The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV).
 
Cindy Jiang
No Relationships to Disclose
 
Omar Alhalabi
Consulting or Advisory Role - Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Ikena Oncology (Inst)
 
Jaime Haro-Silerio
No Relationships to Disclose
 
Wei Qiao
No Relationships to Disclose
 
Amishi Yogesh Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Arlene O. Siefker-Radtke
Honoraria - Janssen
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Gilead Sciences; IDEAYA Biosciences; Janssen; Loxo; Merck; Mirati Therapeutics; Nektar; Seagen; Taiho Oncology
Research Funding - Basilea Pharmaceutical; Bristol-Myers Squibb; Janssen; Merck; Millennium; Mirati Therapeutics; Nektar
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Sangeeta Goswami
No Relationships to Disclose
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck
 
Vadim S. Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte (Inst); Merck (Inst); Nektar (Inst); Taiho Oncology (Inst)
 
Charles Guo
No Relationships to Disclose
 
Matthew T. Campbell
Honoraria - AstraZeneca; Axdev; Curio Science; Exelixis; Medscape; Seagen; Targeted Oncology
Consulting or Advisory Role - EMD Serono; Exelixis; Pfizer; SeaGen
Research Funding - Apricity Health (Inst); Aravive (Inst); Exelixis (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AVEO; SeaGen
Other Relationship - Curio Science